Peak glucose during an oral glucose tolerance test is associated with future diabetes risk in adults with cystic fibrosis.


Journal

Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777

Informations de publication

Date de publication:
06 2021
Historique:
received: 05 11 2020
accepted: 11 01 2021
pubmed: 12 3 2021
medline: 23 2 2022
entrez: 11 3 2021
Statut: ppublish

Résumé

Cystic fibrosis-related diabetes (CFRD) affects up to 50% of adults with cystic fibrosis (CF) and its presence is associated with adverse effects on nutritional status and pulmonary function. Early diagnosis could minimise CFRD morbidity, yet current methods of an OGTT at 0 and 2 h yield unreliable results. Our aim was to determine which indices from a 2 h OGTT with sampling every 30 min might improve prediction of CFRD. Cross-sectional analysis at baseline (n = 293) and observational prospective analysis (n = 185; mean follow-up of 7.5 ± 4.2 years) of the Montreal Cystic Fibrosis Cohort were performed. Blood glucose and insulinaemia OGTT variables were studied in relation to lung function (forced expiratory volume in 1 s [FEV1]), BMI and risk of developing CFRD. At baseline, maximum OGTT glucose (G In adults with CF, G

Identifiants

pubmed: 33693987
doi: 10.1007/s00125-021-05423-5
pii: 10.1007/s00125-021-05423-5
doi:

Substances chimiques

Blood Glucose 0
Insulin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1332-1341

Subventions

Organisme : CIHR
Pays : Canada

Références

Panagopoulou P, Fotoulaki M, Nikolaou A, Nousia-Arvanitakis S (2014) Prevalence of malnutrition and obesity among cystic fibrosis patients. Pediatr Int 56(1):89–94. https://doi.org/10.1111/ped.12214
doi: 10.1111/ped.12214 pubmed: 24003895
Fibrose Kystique Canada (2018) Rapport de données annuel 2017 du Registre canadien sur la fibrose kystique. Available from http://www.fibrosekystique.ca/about-us/rapport-annuel . Accessed 16 Jan 2020 [document in French]
Corey M, McLaughlin FJ, Williams M, Levison H (1988) A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 41(6):583–591. https://doi.org/10.1016/0895-4356(88)90063-7
doi: 10.1016/0895-4356(88)90063-7 pubmed: 3260274
Clancy JP (2018) Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 53(S3):S4–S11. https://doi.org/10.1002/ppul.24157
doi: 10.1002/ppul.24157 pubmed: 30289627 pmcid: 6585954
Bell SC, Mall MA, Gutierrez H et al (2020) The future of cystic fibrosis care: a global perspective. Lancet Respir Med 8(1):65–124. https://doi.org/10.1016/S2213-2600(19)30337-6
doi: 10.1016/S2213-2600(19)30337-6 pubmed: 31570318
Boudreau V, Coriati A, Hammana I et al (2016) Variation of glucose tolerance in adult patients with cystic fibrosis: what is the potential contribution of insulin sensitivity? J Cyst Fibros 15(6):839–845. https://doi.org/10.1016/j.jcf.2016.04.004
doi: 10.1016/j.jcf.2016.04.004 pubmed: 27139162
Costa M, Potvin S, Berthiaume Y et al (2005) Diabetes: a major co-morbidity of cystic fibrosis. Diabetes Metab 31(3 Pt 1):221–232. https://doi.org/10.1016/s1262-3636(07)70189-1
doi: 10.1016/s1262-3636(07)70189-1 pubmed: 16142013
Moran A, Pekow P, Grover P et al (2009) Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 32(10):1783–1788. https://doi.org/10.2337/dc09-0585
doi: 10.2337/dc09-0585 pubmed: 19592632 pmcid: 2752940
Rafii M, Chapman K, Stewart C et al (2005) Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr 81(2):421–426. https://doi.org/10.1093/ajcn.81.2.421
doi: 10.1093/ajcn.81.2.421 pubmed: 15699230
Stephenson AL, Mannik LA, Walsh S et al (2013) Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr 97(4):872–877. https://doi.org/10.3945/ajcn.112.051409
doi: 10.3945/ajcn.112.051409 pubmed: 23388659
Bonhoure A, Boudreau V, Litvin M et al (2020) Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors. Clin Nutr 39(9):2910–2916
doi: 10.1016/j.clnu.2019.12.029
Brennan AL, Gyi KM, Wood DM et al (2007) Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 6(2):101–109. https://doi.org/10.1016/j.jcf.2006.03.009
doi: 10.1016/j.jcf.2006.03.009 pubmed: 16844431
Ntimbane T, Krishnamoorthy P, Huot C et al (2008) Oxidative stress and cystic fibrosis-related diabetes: a pilot study in children. J Cyst Fibros 7(5):373–384. https://doi.org/10.1016/j.jcf.2008.01.004
doi: 10.1016/j.jcf.2008.01.004 pubmed: 18420468
Lanng S, Thorsteinsson B, Nerup J, Koch C (1994) Diabetes mellitus in cystic fibrosis: effect of insulin therapy on lung function and infections. Acta Paediatr 83(8):849–853. https://doi.org/10.1111/j.1651-2227.1994.tb13156.x
doi: 10.1111/j.1651-2227.1994.tb13156.x pubmed: 7981562
Godbout A, Hammana I, Potvin S et al (2008) No relationship between mean plasma glucose and glycated haemoglobin in patients with cystic fibrosis-related diabetes. Diabetes Metab 34(6 Pt 1):568–573. https://doi.org/10.1016/j.diabet.2008.05.010
doi: 10.1016/j.diabet.2008.05.010 pubmed: 18922724
Moran A, Brunzell C, Cohen RC et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33(12):2697–2708. https://doi.org/10.2337/dc10-1768
doi: 10.2337/dc10-1768 pubmed: 21115772 pmcid: 2992215
Walshaw M (2009) Routine OGTT screening for CFRD - no thanks. J R Soc Med 102(Suppl 1):40–44
doi: 10.1258/jrsm.2009.s19009
Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539–553. https://doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
doi: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S pubmed: 9686693
Sylvain C, Lamothe L, Berthiaume Y, Rabasa-Lhoret R (2016) How patients’ representations of cystic fibrosis-related diabetes inform their health behaviours. Psychol Health 31(10):1129–1144. https://doi.org/10.1080/08870446.2016.1183008
doi: 10.1080/08870446.2016.1183008 pubmed: 27112101
Coriati A, Belson L, Ziai S et al (2014) Impact of sex on insulin secretion in cystic fibrosis. J Clin Endocrinol Metab 99(5):1767–1773. https://doi.org/10.1210/jc.2013-2756
doi: 10.1210/jc.2013-2756 pubmed: 24446654
Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23(3):295–301. https://doi.org/10.2337/diacare.23.3.295
doi: 10.2337/diacare.23.3.295 pubmed: 10868854
Prentice BJ, Chelliah A, Ooi CY et al (2019) Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. J Cyst Fibros 19(2):305–309
doi: 10.1016/j.jcf.2019.05.005
Brodsky J, Dougherty S, Makani R, Rubenstein RC, Kelly A (2011) Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis. Diabetes Care 34(2):292–295. https://doi.org/10.2337/dc10-1604
doi: 10.2337/dc10-1604 pubmed: 21228248 pmcid: 3024336
Hameed S, Morton JR, Jaffe A et al (2010) Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33(2):221–226. https://doi.org/10.2337/dc09-1492
doi: 10.2337/dc09-1492 pubmed: 19910502
Boudreau V, Reynaud Q, Bonhoure A, Durieu I, Rabasa-Lhoret R (2019) Validation of a stepwise approach using glycated hemoglobin levels to reduce the number of required oral glucose tolerance tests to screen for cystic fibrosis–related diabetes in adults. Can J Diabetes 43(3):161–162. https://doi.org/10.1016/j.jcjd.2018.11.005
doi: 10.1016/j.jcjd.2018.11.005 pubmed: 30713090
Sheikh S, Gudipaty L, De Leon DD et al (2017) Reduced beta-cell secretory capacity in pancreatic-insufficient, but not pancreatic-sufficient, cystic fibrosis despite normal glucose tolerance. Diabetes 66(1):134–144
doi: 10.2337/db16-0394
Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ (2005) Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146(5):681–687. https://doi.org/10.1016/j.jpeds.2004.12.039
doi: 10.1016/j.jpeds.2004.12.039 pubmed: 15870674
Boudreau V, Reynaud Q, Dubois CL et al (2016) Screening for cystic fibrosis-related diabetes: matching pathophysiology and addressing current challenges. Can J Diabetes 40(5):466–470. https://doi.org/10.1016/j.jcjd.2016.08.221
doi: 10.1016/j.jcjd.2016.08.221 pubmed: 27737759
Lanng S, Thorsteinsson B, Nerup J, Koch C (1992) Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr 151(9):684–687. https://doi.org/10.1007/BF01957574
doi: 10.1007/BF01957574 pubmed: 1396931
Bismuth E, Laborde K, Taupin P et al (2008) Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr 152(4):540–545, 5 e1. https://doi.org/10.1016/j.jpeds.2007.09.025
doi: 10.1016/j.jpeds.2007.09.025 pubmed: 18346512
Cano Megias M, Guisado Vasco P, Gonzalez Albarran O, Lamas Ferreiro A, Maiz Carro L (2015) Association of the relative change in weight and body mass index with lung function in teenagers and adults with cystic fibrosis: Influence of gender and diabetes. Endocrinol Nutr 62(9):422–429. https://doi.org/10.1016/j.endonu.2015.06.009
doi: 10.1016/j.endonu.2015.06.009 pubmed: 26311609
Colomba J, Boudreau V, Lehoux-Dubois C et al (2019) The main mechanism associated with progression of glucose intolerance in older patients with cystic fibrosis is insulin resistance and not reduced insulin secretion capacity. J Cyst Fibros 18(4):551–556. https://doi.org/10.1016/j.jcf.2019.01.009
doi: 10.1016/j.jcf.2019.01.009 pubmed: 30711385
Kern AS, Prestridge AL (2013) Improving screening for cystic fibrosis-related diabetes at a pediatric cystic fibrosis program. Pediatrics 132(2):e512–e518. https://doi.org/10.1542/peds.2012-4029
doi: 10.1542/peds.2012-4029 pubmed: 23821699
Dobson L, Sheldon CD, Hattersley AT (2004) Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med 21(7):691–696. https://doi.org/10.1111/j.1464-5491.2004.01219.x
doi: 10.1111/j.1464-5491.2004.01219.x pubmed: 15209760
Hameed S, Jaffe A, Verge CF (2015) Advances in the detection and management of cystic fibrosis related diabetes. Curr Opin Pediatr 27(4):525–533. https://doi.org/10.1097/MOP.0000000000000251
doi: 10.1097/MOP.0000000000000251 pubmed: 26087430
Coriati A, Elisha B, Virassamynaik S et al (2013) Diagnosis of cystic fibrosis-related glucose abnormalities: can we shorten the standard oral glucose tolerance test? Appl Physiol Nutr Metab 38(12):1254–1259. https://doi.org/10.1139/apnm-2013-0022
doi: 10.1139/apnm-2013-0022 pubmed: 24195626
Quon BS, Sykes J, Stanojevic S et al (2018) Clinical characteristics of cystic fibrosis patients prior to lung transplantation: an international comparison between Canada and the United States. Clin Transpl 32(3):e13188. https://doi.org/10.1111/ctr.13188
doi: 10.1111/ctr.13188

Auteurs

Anne Bonhoure (A)

Montreal Clinical Research Institute, Montreal, QC, Canada.
Division of Experimental Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada.

Kathryn J Potter (KJ)

Montreal Clinical Research Institute, Montreal, QC, Canada.

Johann Colomba (J)

Montreal Clinical Research Institute, Montreal, QC, Canada.
Department of Nutrition, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Valérie Boudreau (V)

Montreal Clinical Research Institute, Montreal, QC, Canada.
Department of Nutrition, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Cindy Bergeron (C)

Montreal Clinical Research Institute, Montreal, QC, Canada.
Department of Nutrition, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.

Katherine Desjardins (K)

Montreal Clinical Research Institute, Montreal, QC, Canada.

Maïté Carricart (M)

Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Cystic Fibrosis Clinic, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.

François Tremblay (F)

Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Cystic Fibrosis Clinic, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.

Annick Lavoie (A)

Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, QC, Canada.
Cystic Fibrosis Clinic, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada.

Rémi Rabasa-Lhoret (R)

Montreal Clinical Research Institute, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Department of Nutrition, Faculty of Medicine, University of Montreal, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.
Cystic Fibrosis Clinic, University of Montreal Hospital Center (CHUM), Montreal, QC, Canada. remi.rabasa-lhoret@ircm.qc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH